The possible hyperplastic effect on the mouse gastric mucosa following administration of 500 mg/kg of ebrotidine for 18 mo was investigated. The animals were taken from the study of carcinogenesis in mouse carried out with this product. Two different aspects were considered to assess such a possible hyperplastic effect. The height of the fundic and antral mucosa was microscopically measured in several points. Histologic sections obtained from standardized levels of the stomach were used. The density of argyrophil cells in the gastric mucosa has been also quantified, in order to identify enterochromaffin-like (ECL) cells, the most abundant among the cells that have this property. Grimelius' silver staining method was used to identify ECL cells. The cell count was performed under ×400 magnification, and the length of mucosa examined was determined by computer-assisted image analysis. This study complements the mouse carcinogenesis study, in which no differences in tumor incidence were found between treated and control animals. The results show that administration of 500 mg/kg/day of ebrotidine for 18 mo to mice did not induce any hyperplastic effect on the gastric mucosa comprising its various cell types or any specific, diffuse, or focal hyperplasia of ECL cells.
Anglada L., Marquez M., sacristán A., and Urtiz JA (1988). Inhibitors of gastric acid secretion. N-sulphonyl formamidines in a series of new histamine H2-receptor antagonists. Eur. J. Med. Chem.23: 97-100.
2.
Axelson J., Håkanson R., Rosengren E., and Sundler F. (1988). Hypergastrinemia induced by acid blockade evokes enterochromaffin-like (ECL) cell hyperplasia in chicken, hamster and guinea-pig stomach. Cell Tissue Res. 254: 511-516.
3.
Betton GR, Dormer CHS, Wells T., Pert P., Pricce CA, and Buckley P. (1988). Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SKF 93479 and oxmetidine and omeprazole. Toxicol. Pathol. 16(2): 288-298.
4.
Brittain RT, Jack D., Reeves JJ, and Stables R. (1985). Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an unsurmountable histamine H2-receptor blocking drug. Br. J. Pharmacol. 85: 843-847.
5.
Capella C. (1980). Gastric carcinoids of argyrophil ECL cells. Ultrastruct. Pathol. 1: 411-418.
6.
Carlsson E., Havu N., Mattsson H., and Ekmon L. (1990). Gastric and gastric enterochromaffin-like cell carcinoids in the rat. Digestion47(suppl.1): 17-23.
7.
Consejo de las Comunidades Europeas (1986). Lineas Directrices relativas al alojamiento y a los cuidados de los animales. Anexo II al Artículo 5 de la Directiva del Consejo de 24 de Noviembre de 1986 respecto a la protección de los animales utilizados para experimentación y otros fines científicos (86/609/CEE). Diario Oficial Comunidad. Eur. 18.12.86, L358: 1-28.
8.
Ekman L., Hansson E., Havu N., Carlsson E., and Lundberg C. (1985). Toxicological studies on omeprazole. Scand. J. Gastroenterol. 20(108): 53-69.
9.
Falcó J., Romero A., Villamayor F., Sacristan A., and Ortiz JA (1992). Caracterización de células enteroendocrinas de la mucosa gástrica de roedor. In: II Simposio de la Sociedad Española de Ciencias del Animal de Laboratorio (SECAL). Programa y Resúmenes . Bellaterra, Barcelona, Spain.
10.
Grimelius L. and Wilander E. (1980). Silver stains in the study of endocrine cells of the gut and pancreas. Invest. Cell Pathol. 3: 3-12.
11.
Håkanson R. and Sunder F. (1986). Gastric carcinoids and antisecretory drugs. Trends Pharmacol. Sci. 7(10): 386-387.
12.
Harvey RF, Bradshaw MJ, Davidson CM, Wilkinson SP, and Davies PS (1985). Multifocal gastric carcinoid tumours, achlorhydria, and hypergastrinemia. Lanceti: 951-953.
13.
Havu N., Mattsson H., Ekman L., and Carlsson E. (1990). Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion45: 189-195.
14.
Hirth RS, Evans LD, Buroker RA, and Oleson FB (1988). Gastric enterochromaffin-like cell hyperplasia and neoplasia in the rat: An indirect effect of the histamine H2-receptor antagonist, BL-6341. Toxicol. Pathol. 16(2): 273-287.
15.
Konturek SJ , Brzowski T., Drozdowicz D., and Majka J. (1991). Ebrotidine a novel H2-receptor antagonist with local gastroprotective activity. Eur. J. Gastroenterol. Hepatol. 3(12): 941-947.
16.
Larsson H., Carlsson E., Mattsson H., Lundell L., Sundler F., Sundler G., Wallmark B., Watanabe T., and Håkanson R. (1986). Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology90: 391-399.
17.
Lee Hong , Håkanson R., Karlsson A., Mattsson H., and Sundler F. (1992). Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastric cells and somatostatin cells in the rat stomach. Digestion52: 125-132.
18.
Maczka M., Kniecien N., Obtulowicz W., Konturek SS, Kaminski K., Olesky J., Gabryelenicz A., and Torres J. (1992). Gastric acid inhibitory profile of ebrotidine, a novel H2-receptor antagonist in humans. J. Physiol. Pharmacol . 43: 2.
19.
Norušis MJ (1990). SPSS/PC+(™) 4.0 Base Manual for the IBM PC/ XT/AT and PS/2. SPSS, Chicago.
20.
Norušis MJ (1990). SPSS/PC+ Statistics(™) 4.0 for the IBM PC/XT/ AT and PS/2. SPSS, Chicago.
21.
Palop D., Conejo L., Sacristan A., and Ortiz JA (1994). Role of nitric oxide in gastroprotective effect of ebrotidine. Comparative study with carbenoxolone. Can. J. Physiol. Pharmacol.72(suppl. 1): 238.
22.
Palop D., Romero A., Villamayor F., Sacristan A., and Ortiz JA (1993). Effect of ebrotidine against gastric mucosal injury induced by ethanol in rats. Comparative study with other H2 receptor antagonists . In: II United European Gastroenterology Week Programme , Barcelona, Spain.
23.
Penston J. (1987). Achlorhydria: Hypergastrinemia: Carcinoids-A flawed hypothesis? Gut28: 488-505.
24.
Poynter D., Pick CR, Harcourt RA, Selway SAM, Ainge G., Harwan IW, Spurling NW, Fluck PA, and Cook JL (1985). Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat. Gut26: 1284-1295.
25.
Poynter D., Selway SAM, Papworth SA, and Riches SR (1986). Changes in the gastric mucosa of the mouse associated with long lasting unsurmountable histamine H2 blockade. Gut27: 1338-1346.
26.
Romero A., Rives A., Grau MT, Villamayor F., Sacristan A., and Ortiz JA (1993). Carcinogenicity studies of ebrotidine in mice. Eurotox '93, Uppsala, Sweden.
27.
Ryberg B., Bishop AE, Bloom SR, Carlsson E., Håkanson R., Larsson H., Mattsson H., Polak JM, and Sundler F. (1989). Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplastic of enterochromaffin-like cells in rat stomach. Regul. Pept. 25: 235-246.
28.
Slomiany BL , Piotrowski J., Mojtahed H., and Slomiany A. (1992). Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori. Gen. Pharmacol. 23(2): 203-206.
29.
Slomiany BL , Piotrowski J., Murty VLN, and Slomiany A. (1992). Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol. Gen. Pharmacol. 23(4): 719-727.
30.
Street CS, Cimprich RE, and Roberston JL (1984). Pathologic findings in the stomachs of rats treated with the H2-receptor antagonist tiotidine. Scand. J. Gastroenterol . 19(101): 109-117.
31.
Street CS, Roberston JL, and Crissman JW (1988). Morphologic stomach findings in rats and mice treated with the H2 receptor antagonists, ICI 125, 211 and ICI 162, 846. Toxicol. Pathol.16(2): 299-304.
32.
Wallmark B. , Skånberg I., Mattsson H., Andersson K., Sundler F., Håkanson R., and Carlsson E. (1990). Effect of 20 weeks ranitidine treatment on plasma gastrin levels and gastric enterochromaffin-like cell density in the rat. Digestion45: 181-188.
